Benzhydryl Compounds
"Benzhydryl Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds which contain the methyl radical substituted with two benzene rings. Permitted are any substituents, but ring fusion to any of the benzene rings is not allowed.
Descriptor ID |
D001559
|
MeSH Number(s) |
D02.455.426.559.389.115
|
Concept/Terms |
Benzhydryl Compounds- Benzhydryl Compounds
- Compounds, Benzhydryl
- Diphenylmethyl Compounds
- Compounds, Diphenylmethyl
|
Below are MeSH descriptors whose meaning is more general than "Benzhydryl Compounds".
Below are MeSH descriptors whose meaning is more specific than "Benzhydryl Compounds".
This graph shows the total number of publications written about "Benzhydryl Compounds" by people in this website by year, and whether "Benzhydryl Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1989 | 0 | 2 | 2 | 1990 | 1 | 0 | 1 | 1994 | 1 | 0 | 1 | 2001 | 1 | 0 | 1 | 2003 | 3 | 0 | 3 | 2004 | 1 | 1 | 2 | 2005 | 1 | 1 | 2 | 2007 | 2 | 0 | 2 | 2008 | 1 | 0 | 1 | 2009 | 3 | 1 | 4 | 2010 | 4 | 0 | 4 | 2011 | 1 | 1 | 2 | 2012 | 1 | 0 | 1 | 2014 | 1 | 1 | 2 | 2015 | 1 | 1 | 2 | 2016 | 0 | 1 | 1 | 2017 | 1 | 0 | 1 | 2018 | 0 | 2 | 2 | 2019 | 1 | 0 | 1 | 2020 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Benzhydryl Compounds" by people in Profiles.
-
Kohn OF. In CKD, the effect of dapagliflozin on kidney outcomes did not vary by T2DM status or CKD cause. Ann Intern Med. 2021 05; 174(5):JC53.
-
Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, Macaluso F, Sartori S, Roque M, Sabatel-Perez F, Rodriguez-Cordero A, Zafar MU, Fergus I, Atallah-Lajam F, Contreras JP, Varley C, Moreno PR, Abascal VM, Lala A, Tamler R, Sanz J, Fuster V, Badimon JJ. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol. 2021 01 26; 77(3):243-255.
-
Kraus BJ, Weir MR, Bakris GL, Mattheus M, Cherney DZI, Sattar N, Heerspink HJL, Ritter I, von Eynatten M, Zinman B, Inzucchi SE, Wanner C, Koitka-Weber A. Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int. 2021 03; 99(3):750-762.
-
Sternlicht HK, Bakris GL. Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes? Lancet Diabetes Endocrinol. 2020 07; 8(7):553-555.
-
Santos-Gallego CG, Garcia-Ropero A, Mancini D, Pinney SP, Contreras JP, Fergus I, Abascal V, Moreno P, Atallah-Lajam F, Tamler R, Lala A, Sanz J, Fuster V, Badimon JJ. Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity? Cardiovasc Drugs Ther. 2019 02; 33(1):87-95.
-
Modi PK, Wang Y, Kirk PS, Dupree JM, Singer EA, Chang SL. The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications. Urology. 2018 Jul; 117:50-56.
-
Plutzky J, Bakris G. Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page. Circulation. 2018 01 09; 137(2):130-133.
-
Deng JH, Lu TB, Sun CC, Chen JM. Dapagliflozin-citric acid cocrystal showing better solid state properties than dapagliflozin. Eur J Pharm Sci. 2017 Jun 15; 104:255-261.
-
Batra J, Tripathi S, Kumar A, Katz JM, Cox NJ, Lal RB, Sambhara S, Lal SK. Human Heat shock protein 40 (Hsp40/DnaJB1) promotes influenza A virus replication by assisting nuclear import of viral ribonucleoproteins. Sci Rep. 2016 Jan 11; 6:19063.
-
DiPersio JF, Erba HP, Larson RA, Luger SM, Tallman MS, Brill JM, Vuagniaux G, Rouits E, Sorensen JM, Zanna C. Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study. Clin Lymphoma Myeloma Leuk. 2015 Jul; 15(7):443-9.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|